http://www.xconomy.com/seattle/2009/05/22/vulcans-biotech-windfall-bipar-sciences-sparks-fundamental-cancer-advance/ Business + Technology in the Exponential Economy Sun, 22 Nov 2009 19:43:29 -0600 http://wordpress.org/?v=2.8.6 hourly 1 http://www.xconomy.com/seattle/2009/05/22/vulcans-biotech-windfall-bipar-sciences-sparks-fundamental-cancer-advance/comment-page-1/#comment-62768 The Medical Quack: BiPar Helps Women Live Longer – Breast Cancer Tue, 02 Jun 2009 07:28:06 +0000 http://www.xconomy.com/?p=25988#comment-62768 [...] Billionaire Paul Allen made windfall profits from his investment in BiPar Sciences, and today we can really see why. The Brisbane, CA-based biotech company founded by Allen’s Vulcan investment firm said today that its drug candidate for women with an aggressive form of breast cancer was able to help them live longer without adding side effects to standard chemotherapy. [...] [...] Billionaire Paul Allen made windfall profits from his investment in BiPar Sciences, and today we can really see why. The Brisbane, CA-based biotech company founded by Allen’s Vulcan investment firm said today that its drug candidate for women with an aggressive form of breast cancer was able to help them live longer without adding side effects to standard chemotherapy. [...]

]]> http://www.xconomy.com/seattle/2009/05/22/vulcans-biotech-windfall-bipar-sciences-sparks-fundamental-cancer-advance/comment-page-1/#comment-62383 ASCO Weekend Roundup Part 1 - Focus on BiPar | IguanaBio - A Daily Biotech and Pharma Tabloid - Gossip, News, Research, Humor and Updates on the Latest Events in Biotech and Pharma - Unique, Insightful, Truthful, Sometimes Sneaky Mon, 01 Jun 2009 09:59:13 +0000 http://www.xconomy.com/?p=25988#comment-62383 [...] The news is getting a lot of hype/press: coverage on Xconomy, coverage on Forbes, this great Bloomberg write-up and the fact that BiPar’s 5-year financing tour de force was led by Microsoft founder Paul Allen’s investment firm Vulcan Capital. [...] [...] The news is getting a lot of hype/press: coverage on Xconomy, coverage on Forbes, this great Bloomberg write-up and the fact that BiPar’s 5-year financing tour de force was led by Microsoft founder Paul Allen’s investment firm Vulcan Capital. [...]

]]> http://www.xconomy.com/seattle/2009/05/22/vulcans-biotech-windfall-bipar-sciences-sparks-fundamental-cancer-advance/comment-page-1/#comment-59661 Luke Timmerman Fri, 22 May 2009 23:05:48 +0000 http://www.xconomy.com/?p=25988#comment-59661 It's true that the BiPar purchase price depends on milestones. The companies didn't disclose what they are, or how much of the purchase price remains to be received. It’s true that the BiPar purchase price depends on milestones. The companies didn’t disclose what they are, or how much of the purchase price remains to be received.

]]> http://www.xconomy.com/seattle/2009/05/22/vulcans-biotech-windfall-bipar-sciences-sparks-fundamental-cancer-advance/comment-page-1/#comment-59653 biobear Fri, 22 May 2009 22:46:34 +0000 http://www.xconomy.com/?p=25988#comment-59653 How much of BiPar's purchase price will be realized initially? Isn't the entire purchase price contingent on more milestones being hit? How much of BiPar’s purchase price will be realized initially? Isn’t the entire purchase price contingent on more milestones being hit?

]]>